Jaahnavi Kandula, the Indian student who was struck and killed by a speeding police car here will be awarded her master's degree posthumously, the Chancellor of Northeastern University has announced, hoping that the ongoing probe will bring a measure of justice and accountability.
'This committee underscores the Indian State's longstanding conventional approach to leverage top-down conflict management in North East India in general and Manipur in particular.' 'Trying to 'manage' violent conflicts top-down has not worked in the past, and apparently does not seem to work this time either.'
The company is demerging its new chemical entity research unit into a separate company to meet the demands of increased spend on research and development, and to insulate investors from the risks involved. According to the deal signed with Merck, NPIL will discover and develop new drugs for two selected targets provided by Merck in the area of cancer.
They said after examining and analysing the adverse event reports, causal relationship and all related details shared by or to be shared by the WHO, the committee will advise and recommend further course of action to the Drugs Controller General of India (DCGI).
The USTR has placed India on its "priority watch" list for two years in a row, saying the country's patent laws unfairly favour local drug makers.
India's largest listed pharmaceutical (pharma) company - Sun Pharmaceutical Industries (Sun Pharma) - is expected to maintain its outperformance vis--vis the sector's, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages. While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent. Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma's minus 1.4 per cent.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
Under Glenmark's 2004 collaborative deal with Forest, the latter had the right to develop and sell the asthma and chronic obstructive pulmonary disorder drug in North America for an upfront payment and additional fees for each developmental milestone that could total $190 million in all. Upon commercialisation, Glenmark will retain the rights for selling the drug for the rest of the world while Forest will continue to sell the drug in North American.
New drug discovery and contract research have taken a back seat as global drug majors have slowed down their research and development offshoring to India.
Around 300 terrorists are present in Jammu and Kashmir, while 160 others are waiting on the launchpads for an opportunity to sneak into this side from across the Line of Control (LoC) in Pakistan, a top army commander said on Tuesday.
Strides Arcolab Ltd's, US subsidiary Strides Inc and STADA Pharmaceuticals Inc, the US subsidiary of STADA Arzneimittel AG, have signed a development and supply agreement for a prescription generic drug product for the US market.
The vaccine is a live form of a different strain of Mycobacterium, the bacteria that cause tuberculosis, a Council of Scientific and Industrial Research report said.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
Scientists have developed a new and more effective drug to help smokers quit the habit, which is known to reduce the life span of those addicted by about 10 years and is the single most important factor for heart attacks the world over.
In a victory for Indian drug companies, patent protection has been refused to Tenofovir, an anti-AIDS medicine of the US-based Gilead Sciences. The decision was taken by the patent office in New Delhi.
Centre mulls strategy to ensure powers given to the agencies are not misused.
They seek to profit from big-selling drugs going off-patent this year in the lucrative market.
Nirma's tryst with the pharmaceutical space started in 2006 when it acquired the ailing Core Healthcare in a deal reported to be worth Rs 300 crore. The Ahmedabad-based manufacturer of intravenous fluids was subsequently renamed Nirlife. Pharma industry insiders say Nirma, which broke open the detergent market in the 1990s with low prices and massive advertising, tried an encore of the low-price strategy in pharma, but with mixed results.
ABRPL is working on developing drugs for anaemia, cancer and arthritis, said Bruce Murdoch, chief business officer, Avesthagen. "We are targeting high-end products that are going off-patent and are not working on popular soon-to-be off-patent biotech molecules. We should be able to bring a couple of molecules into the commercialisation stage next year," he said.
We have the workforce, now we need to ensure that we take full advantage of game-changing technologies and geopolitical openings, suggests Jayant Sinha, chairman, Parliament's Standing Committee on Finance.
Western drugmakers, including Pfizer Inc, Novartis AG, Roche Holding AG and Sanofi SA, covet a bigger share of the fast-growing Indian drugs market.
'You ain't seen anything yet,' EAM Jaishankar says about the India-US relationship.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
The Duke Clinical Research Institute study found that majority of the paediatric trials enrolled patients in at least one country outside the US.
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
'The worst case scenario is a rebound of the virus.' 'Life is not going to be what it was.' 'Life as we know it has changed forever.' 'The new normal therefore is test, trace and treat.'
'Sharapova has been a US resident since early in her career, which does bring in a question of how or why she is using a drug that is not licensed there'
The move comes after international studies revealed that Gatifloxacin posed 17 times higher risk of developing serious hyperglycemia than other antibiotics in elderly patients.
market, was today seized from an illegal drug manufacturing unit in Jalgaon district in north Maharashtra and six persons were arrested, Directorate of Revenue Intelligence officials said.
The drugs manufacturing industry is on a state of alert following two landmark developments over a cancer treatment medicine.
NPPA suggests expanding the list of essential medicines whose prices are controlled
In contrast with their strong performance in 2020 and 2021, pharmaceutical and healthcare funds experienced a decline in 2022, with returns plummeting by an average 9.8 per cent. This trend has continued in the current year, with year-to-date return remaining in the negative (-4.9 per cent). In the past three months, pharma funds have been hit hard, experiencing a 7.9 per cent decline.
According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin.
Police officer Harminder Phagura is busted for aiding a 'friend' in carrying out cocaine deals.
Vasundhara Raje may have had her faults but she is an unconventional and brave leader who deserves better, observes Aditi Phadnis.
Ranbaxy Laboratories has decided to separate the two areas of research and development - drug discovery and generics/NDDS/drug development - to achieve increased focus and rigour for success.
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
'We would like to develop Andhra Pradesh into a logistics hub not only for India, but also for South Asia.'
The government should take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget, as per pharmaceutical industry bodies. Outlining the wish list for the sector in the upcoming Union Budget, Indian Pharmaceutical Alliance (IPA) secretary general Sudarshan Jain said the domestic pharma industry is currently around $50 billion in size and aspires to grow to around $130 billion by 2030 and $450 billion by 2047. "To achieve this vision, the Union Budget 2023-2024 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry forward," he told PTI.
'Gift-giving' - from free dinners and drug samples to promotional merchandise - seems to be driving drugmakers' marketing - a marketing prescription deeply entrenched in the industry. This is a well-oiled racket that sees pharmaceutical (pharma) companies 'gifting' doctors to push their respective drugs under the guise of marketing. But is there a cure in sight to end this unhealthy alliance? The recent controversy following the income-tax raids on Bengaluru-based drugmaker Micro Labs, makers of popular paracetamol brand Dolo-650, has brought this to the fore, again.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances